{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:58:36Z","timestamp":1781650716183,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hyperkalemia (serum potassium\u2009&gt;\u20095.0 mmol\/L) is a common and clinically significant complication in patients with chronic kidney disease (CKD), particularly among those treated with renin-angiotensin-aldosterone system inhibitors (RAASi). Although guideline-directed medical therapy recommends proactive hyperkalemia management to enable continued RAASi use, real-world practice remains suboptimal. Key challenges include inadequate potassium monitoring after RAASi initiation or dose escalation, unnecessary RAASi dose reduction or discontinuation following hyperkalemia episodes, and poor long-term treatment adherence. Moreover, evidence regarding the cardio-renal benefits of RAASi optimization supported by structured hyperkalemia management in Chinese CKD populations is limited. This study aims to bridge the gap between Kidney Disease: Improving Global Outcomes (KDIGO) and Chinese CKD guideline recommendations and routine clinical practice through a nationwide quality improvement program (QIP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, multicenter, single-arm study will enroll approximately 1,000 adult Chinese patients with non-dialysis CKD and hyperkalemia across 50 sites. The QIP includes comprehensive and reinforcement training for healthcare professionals (HCPs) based on the KDIGO 2024 guidelines, supported by regular quality audits and feedback. Patient-directed interventions comprise structured education delivered by HCPs and self-learning modules. Participants will receive standardized hyperkalemia management over 96 weeks, including protocolized serum potassium monitoring (every 3 months or monthly for high-risk patients), RAASi dose optimization, and long-term potassium control. The primary endpoint is the proportion of patients achieving RAASi optimization with normokalemia (3.5-5.0 mmol\/L) at 48 weeks. Secondary endpoints include sustained potassium control, RAASi optimization over time, medication adherence, hyperkalemia recurrence and severity, cardiorenal outcomes, and safety endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>As the first nationwide QIP focusing on hyperkalemia management in CKD patients in China, this study is expected to provide real-world evidence on the effectiveness of standardized hyperkalemia care in facilitating sustained RAASi use. By aligning clinical practice with guideline recommendations, the program has the potential to improve long-term cardio-renal outcomes and inform future CKD care strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, NCT06884267; registered March 13, 2025.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-04801-8","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:35:58Z","timestamp":1776789358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study protocol for a prospective, multicenter, single-arm study investigating the impact of the implementation of standardized hyperkalemia management in chronic kidney disease patients"],"prefix":"10.1186","volume":"27","author":[{"given":"Yeqing","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuhua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"4801_CR1","doi-asserted-by":"crossref","unstructured":"Palmer BF, Carrero JJ, Clegg DJ, Colbert GB, Emmett M, Fishbane S, et al. Clinical Management of Hyperkalemia. Mayo Clinic Proceedings. 2021;96:744\u2009\u2013\u200962.","DOI":"10.1016\/j.mayocp.2020.06.014"},{"key":"4801_CR2","first-page":"S10","volume":"23","author":"ZWM Rafique","year":"2017","unstructured":"Rafique ZWM, Onuigbo M, Pitt B, Lafayette R, Butler J, Lopes M, Farnum C, Peacock WF. Expert panel recommendations for the identification and management of hyperkalemia and role of patiromer in patients with chronic kidney disease and heart failure. J Manag Care Spec Pharm. 2017;23:S10\u20139.","journal-title":"J Manag Care Spec Pharm"},{"key":"4801_CR3","doi-asserted-by":"crossref","unstructured":"Palaka E, Grandy S, Darlington O, McEwan P, Doornewaard A. Associations between serum potassium and adverse clinical outcomes: a systematic literature review. Int J Clin Pract. 2019;74.","DOI":"10.1111\/ijcp.13421"},{"key":"4801_CR4","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.ekir.2019.05.018","volume":"4","author":"N Kashihara","year":"2019","unstructured":"Kashihara N, Kohsaka S, Kanda E, Okami S, Yajima T. Hyperkalemia in Real-World patients under continuous medical care in Japan. Kidney Int Rep. 2019;4:1248\u201360.","journal-title":"Kidney Int Rep"},{"key":"4801_CR5","doi-asserted-by":"crossref","unstructured":"Valdivielso JM, Balafa O, Ekart R, Ferro CJ, Mallamaci F, Mark PB, et al. Hyperkalemia in chronic kidney disease in the new era of kidney protection therapies. Drugs. 2021;8.","DOI":"10.1007\/s40265-021-01555-5"},{"key":"4801_CR6","first-page":"726","volume":"19","author":"JM Bian","year":"2020","unstructured":"Bian JM, Zuo L, Zhao HY, Han X. Epidemiology and treatment pattern of hyperkalaemia among outpatients in china: a descriptive study using an administrative database in China. Chin J Blood Purif. 2020;19:726\u20139.","journal-title":"Chin J Blood Purif"},{"key":"4801_CR7","doi-asserted-by":"publisher","first-page":"e035256","DOI":"10.1161\/JAHA.124.035256","volume":"14","author":"A Agiro","year":"2025","unstructured":"Agiro A, Mu F, Cook E, Greatsinger A, Chen J, Zhao A, et al. Hyperkalemia and the risks of adverse cardiovascular outcomes in patients with chronic kidney disease. J Am Heart Assoc. 2025;14:e035256.","journal-title":"J Am Heart Assoc"},{"key":"4801_CR8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.mayocpiqo.2020.10.001","volume":"5","author":"S Kohsaka","year":"2021","unstructured":"Kohsaka S, Okami S, Kanda E, Kashihara N, Yajima T. Cardiovascular and renal outcomes associated with hyperkalemia in chronic kidney disease: A Hospital-Based cohort study. Mayo Clin Proc Innov Qual Outcomes. 2021;5:274\u201385.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"4801_CR9","doi-asserted-by":"publisher","first-page":"R225","DOI":"10.1186\/cc11872","volume":"16","author":"JN An","year":"2012","unstructured":"An JN, Lee JP, Jeon HJ, Kim DH, Oh YK, Kim YS, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care. 2012;16:R225.","journal-title":"Crit Care"},{"key":"4801_CR10","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","volume":"109","author":"N Jain","year":"2012","unstructured":"Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109:1510\u20133.","journal-title":"Am J Cardiol"},{"key":"4801_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.kisu.2016.01.004","volume":"6","author":"M Epstein","year":"2016","unstructured":"Epstein M. Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney Int Suppl (2011). 2016;6:20\u20138.","journal-title":"Kidney Int Suppl (2011)"},{"key":"4801_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejim.2024.03.021","volume":"125","author":"S Jimenez-Marrero","year":"2024","unstructured":"Jimenez-Marrero S, Cainzos-Achirica M, Monterde D, Vela E, Enjuanes C, Yun S, et al. Serum potassium abnormalities, renin-angiotensin-aldosterone system inhibitor discontinuation, and clinical outcomes in patients with chronic cardiovascular, metabolic, and renal conditions: A population-based analysis. Eur J Intern Med. 2024;125:89\u201397.","journal-title":"Eur J Intern Med"},{"key":"4801_CR13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12882-022-03054-5","volume":"24","author":"E Kanda","year":"2023","unstructured":"Kanda E, Rastogi A, Murohara T, Lesen E, Agiro A, Arnold M, et al. Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol. 2023;24:18.","journal-title":"BMC Nephrol"},{"key":"4801_CR14","doi-asserted-by":"publisher","first-page":"e074216","DOI":"10.1136\/bmj-2022-074216","volume":"383","author":"TK Chen","year":"2023","unstructured":"Chen TK, Hoenig MP, Nitsch D, Grams ME. Advances in the management of chronic kidney disease. BMJ. 2023;383:e074216.","journal-title":"BMJ"},{"key":"4801_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000531000","volume":"54","author":"C Tang","year":"2023","unstructured":"Tang C, Wen X-Y, Lv J-C, Shi S-F, Zhou X-J, Liu L-J, et al. Discontinuation of Renin-Angiotensin system inhibitors and clinical outcomes in chronic kidney disease: A systemic review and Meta-Analysis. Am J Nephrol. 2023;54:234\u201344.","journal-title":"Am J Nephrol"},{"key":"4801_CR16","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726.","journal-title":"Eur Heart J"},{"key":"4801_CR17","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117\u2013314.","journal-title":"Kidney Int"},{"key":"4801_CR18","first-page":"781","volume":"36","author":"Expert Group of Chinese Society of Nephrology","year":"2020","unstructured":"Expert Group of Chinese Society of Nephrology. Expert consensus on the management of sserum K\u2009+\u2009in chronic kidney disease patients in China (2020). Chin J Nephrol. 2020;36:781\u201392.","journal-title":"Chin J Nephrol"},{"key":"4801_CR19","first-page":"902","volume":"62","author":"Professional Committee on Prevention and Control of Kidney Diseases of the Chinese Preventive Medicine Association","year":"2023","unstructured":"Professional Committee on Prevention and Control of Kidney Diseases of the Chinese Preventive Medicine Association. Guidelines for the early evaluation and management of chronic kidney disease in China (2023). Chin J Intern Med. 2023;62:902\u201330.","journal-title":"Chin J Intern Med"},{"key":"4801_CR20","doi-asserted-by":"publisher","first-page":"112413","DOI":"10.1016\/j.diabres.2025.112413","volume":"227","author":"X Hao","year":"2025","unstructured":"Hao X, Liu J, Gu L, Zang X, Liu N, Pan Y, et al. Sodium zirconium cyclosilicate (Lokelma) to enable ACEIs\/ARBs use in the treatment of patients with diabetic kidney disease. Diabetes Res Clin Pract. 2025;227:112413.","journal-title":"Diabetes Res Clin Pract"},{"key":"4801_CR21","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1007\/s12325-023-02518-w","volume":"40","author":"A Agiro","year":"2023","unstructured":"Agiro A, An A, Cook EE, Mu F, Chen J, Desai P, et al. Real-World modifications of Renin-Angiotensin-Aldosterone system inhibitors in patients with hyperkalemia initiating sodium zirconium cyclosilicate therapy: the OPTIMIZE I study. Adv Ther. 2023;40:2886\u2013901.","journal-title":"Adv Ther"},{"key":"4801_CR22","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1007\/s12325-025-03254-z","volume":"42","author":"A Agiro","year":"2025","unstructured":"Agiro A, Greatsinger A, Mu F, Cook EE, Chen J, Sundar M, et al. Renin-Angiotensin-Aldosterone system inhibitor dosing after initiation of outpatient sodium zirconium cyclosilicate therapy: the GALVANIZE RAASi Real-World evidence study. Adv Ther. 2025;42:3960\u201377.","journal-title":"Adv Ther"},{"key":"4801_CR23","doi-asserted-by":"crossref","unstructured":"Luo W, Huang H, Zhou Y, Min J, Wang C. Implementation of pharmaceutical strategies using the PDCA cycle for standardized management of cancer pain medications. Support Care Cancer. 2025;33.","DOI":"10.1007\/s00520-025-09228-9"},{"key":"4801_CR24","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1007\/s00701-022-05347-y","volume":"164","author":"A Abdulazim","year":"2022","unstructured":"Abdulazim A, K\u00fcppers C, Hackenberg KAM, Neumaier-Probst E, Alzghloul MM, Krebs J, et al. Multidisciplinary and standardized management of patients with delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Acta Neurochir. 2022;164:2917\u201326.","journal-title":"Acta Neurochir"},{"key":"4801_CR25","doi-asserted-by":"publisher","first-page":"A5254","DOI":"10.1164\/ajrccm.2025.211.Abstracts.A5254","volume":"211","author":"K Huang","year":"2025","unstructured":"Huang K, Shi H, Huang S, Li Y, Lv X, Bai X, et al. Improving asthma management and patient outcomes in China through a quality improvement programme: A Multi-centre, Single-arm study (CARE4ALL). Am J Respir Crit Care Med. 2025;211:A5254\u2013A.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04801-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04801-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04801-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:30:36Z","timestamp":1781649036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04801-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4801"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04801-8","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was given ethical approval by Ethics Committee of Zhongshan Hospital Fudan University (approval reference B2024-548R), and all patients will be enrolled voluntarily, with the option to withdraw consent at any time during the study. Written informed consent will be obtained from all study participants prior to participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qing Li is employed by Astrazeneca Investment (China) Co. LTD. Other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"354"}}